CANARY ISLANDS WEEKLY EDITORIAL / AGENCIES
The company Pfizer Inc, producer of the vaccine against Covid 19, reported this Tuesday that it expects that in 2022 the sales of its vaccine against COVID-19, as well as “his antiviral pill”, reach the $54 billion.
However, the sales estimates made by the stock market Wall Street they have not been fulfilled and their shares have fallen by around 3%.
The CEO of the company, Albert Bourla, stated that the final sales of its oral antiviral against COVID-19 could become “considerably higher” to the figures that the company previously Pfizer had calculated.
“Clearly, this is only a fraction of the 120 million treatments that we are currently preparing to manufacture” this year, manifested Bourla economic analysts in a conference call.
Last year the company Pfizer It considerably multiplied its forecast for sales of vaccines against COVID, also multiplying the signing of agreements to supply vaccines to the entire world.
Analysts, however, have forecast sales this year that will reach 33.79 billion, according to data from Refinitiv.
Pfizer, however, expects to achieve by the present 2022 sales encrypted between the 98 billion and the 102 billion of dollars.
–
